Sufentanil
( DrugBank: Sufentanil / KEGG DRUG: Sufentanil citrate, Sufentanil )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 1 |
| 22 | Moyamoya disease | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 2 |
| 280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 1 |
11. Myasthenia gravis
Clinical trials : 439 / Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
22. Moyamoya disease
Clinical trials : 23 / Drugs : 29 - (DrugBank : 21) / Drug target genes : 35 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
70. Spinal stenosis
Clinical trials : 127 / Drugs : 178 - (DrugBank : 67) / Drug target genes : 87 - Drug target pathways : 99
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 29 / Drugs : 31 - (DrugBank : 15) / Drug target genes : 12 - Drug target pathways : 163
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|